Anzeige
Mehr »
Samstag, 27.12.2025 - Börsentäglich über 12.000 News
Breaking News: Das "Schweizer Messer" für Diabetiker ist da!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von BioPharma Dive

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
14.11.Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal
14.11.Merck stakes $9.2B on Cidara and its long-acting flu drug
14.11.Medicxi closes fifth fund to back 'asset-centric' startups
13.11.Day One snaps up ADC maker Mersana in backloaded buyout deal
13.11.Korro to cut staff, shift strategy as RNA editing drug misses mark in early testing
12.11.Novartis, with study success, to seek approval of new kind of malaria drug
12.11.FDA unveils new regulatory roadmap for bespoke drug therapies
12.11.Richard Pazdur, longtime FDA oncology leader, to head agency's main drug office
12.11.Metagenomi, Ovid CEOs step aside; Cogent soars on 'unprecedented' stomach cancer data
11.11.Neurocrine chalks up a depression drug failure
10.11.FDA to remove safety warnings on hormonal menopause therapy
10.11.Roche's MS tablet scores in late-stage studies
10.11.Merck showcases data suggesting PCSK9 pill might rival cholesterol-lowering shots
10.11.Lilly picks up an eye gene therapy in deal with MeiraGTx
07.11.CMS to launch model to lower Medicaid drug spending
07.11.Patient dies in Intellia trial; FDA awards 6 more 'national priority' vouchers
07.11.Pharma's clinical trial diversity push faces a new threat
06.11.Novo, Lilly cut deal with Trump to lower prices of obesity drugs
06.11.AstraZeneca exercises option to buy an obesity startup
06.11.Moderna leans on cost cuts, pipeline as vaccine sales dip
06.11.J&J brain drug acquired in $14.6B buyout cleared for broader use
06.11.Evommune nabs $150M in IPO amid federal shutdown
05.11.Knocked back by the FDA, Biohaven turns to major cost cuts
05.11.Soleno slumps despite sales uptick; Madrigal's MASH drug continues ascent
05.11.Novo narrows sales outlook as GLP-1 price cuts loom